Defense Partnerships OXYVITA already has a CRADA with the U.S. Navy, signaling a viable path to defense medical contracts and field testing of oxygen therapeutics. BD opportunities include expanding DoD collaborations, pilot programs in trauma and emergency medicine, and strategic sourcing agreements for future blood substitute supply once approved.

Academic Access The company currently supplies products to independent researchers and is advancing preclinical work. There is an opportunity to broaden distribution to universities and research labs through pilot programs, volume pricing, and research-use licenses, creating recurring revenue while accelerating clinical viability.

Licensing Strategy OXYVITA's Zero-Link polymerization technology is a differentiator with licensing potential for biotech and pharma players developing oxygen carriers or RBC substitutes. Consider co-development licenses, milestone-based payments, and royalties to monetize the platform and de-risk clinical development for partners.

Funding Pathways With fundraising aimed at completing animal studies and FDA applications, there is room to engage venture investors and government funding programs. Target opportunities include government grants, translational research programs, and strategic partnerships that provide capital to accelerate regulatory submissions and any scale-up plans.

Blood Substitution Market The oxygen therapeutic product addresses donor blood limitations and transfusion risks, creating a compelling value proposition for early market entry when approved. Potential buyers include medical centers, blood banks, military medical logistics, and humanitarian organizations seeking safer, readily available oxygen transport solutions.